FACTS:
– Investec Bank Plc filed Form 8.5 (EPT/RI) regarding Advanced Medical Solutions Group Plc
– Filing date: 11th November 2026
– Dealing date: 10th November 2026
– Investec is Advisor & Joint Broker to Advanced Medical Solutions Group Plc
– Investec is an exempt principal trader with recognised intermediary status
– Transaction: Purchase of 269,491 ordinary shares in Advanced Medical Solutions Group Plc
– Highest price paid per unit: 282.75p
– Lowest price paid per unit: 282.556p
– No cash-settled derivatives, no stock-settled derivatives, no other dealings
– No indemnity or option arrangements
– No agreements relating to options or derivatives
– Contact: Abhishek Gawde, +91-9923757332
– Tickers: AMS.L, INL.JO, INVP.L
– Rule 8.5 of the Takeover Code governs this disclosure
– N/A for other party to offer (cash offer or possible cash offer)
ANGLE: Lead with the scale and price of the share purchase, then contextualize the regulatory disclosure and Investec’s dual role, then cover the deal mechanics and what the filing signals about the offer process. Bury the procedural details at the end.
HEADLINE: Investec Bank (INVP.L) Acquires Over 269,000 Advanced Medical Solutions (AMS.L) Shares In Single-Day Purchase
Investec Bank Plc bought 269,491 ordinary shares in Advanced Medical Solutions Group Plc (AMS.L) on 10th November 2026, with prices ranging narrowly between 282.556p and 282.75p per unit.
The purchase, executed within a tight price band of less than 0.2p, points to a concentrated and deliberate accumulation of stock during a single trading session on behalf of clients.
Investec disclosed the transaction publicly on 11th November 2026 through a Form 8.5 filing under Rule 8.5 of the Takeover Code, which governs dealings by exempt principal traders acting in a client-serving capacity.
The bank holds recognised intermediary status, meaning it is permitted to trade in relevant securities during an offer period without triggering certain restrictions that would otherwise apply to connected parties.
Investec’s position in this transaction carries particular weight given that the bank simultaneously serves as Advisor and Joint Broker to Advanced Medical Solutions Group Plc itself.
That dual role places Investec under an obligation to report any dealings in AMS shares promptly and transparently to a Regulatory Information Service, as required by the Takeover Panel’s rules.
The filing confirms no cash-settled derivatives, no stock-settled derivative transactions, and no other dealings were conducted alongside the outright share purchase on that date.
Investec also declared that no indemnity arrangements, option agreements, or understandings of any kind exist between itself and any party to the offer that might constitute an inducement to deal or refrain from dealing.
Similarly, the bank confirmed the absence of any formal or informal agreements relating to voting rights or future acquisition and disposal of securities referenced by any derivative instrument.
Advanced Medical Solutions Group Plc, a UK-listed medical device and wound care company, is the subject of a possible cash offer, with the Form 8.5 filing marked N/A for disclosures relating to any additional offeror or offeree party.
The Takeover Panel’s Market Surveillance Unit oversees compliance with dealing disclosure obligations under the Code, and any parties seeking guidance on those requirements may contact the unit directly at its London office.
